170 related articles for article (PubMed ID: 24966207)
1. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma.
Sato Y; Fujimoto D; Shibata Y; Seo R; Suginoshita Y; Imai Y; Tomii K
Jpn J Clin Oncol; 2014 Sep; 44(9):872-5. PubMed ID: 24966207
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib-induced fatal fulminant liver failure.
van Geel RM; Hendrikx JJ; Vahl JE; van Leerdam ME; van den Broek D; Huitema AD; Beijnen JH; Schellens JH; Burgers SA
Lung Cancer; 2016 Mar; 93():17-9. PubMed ID: 26898609
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
Brosnan EM; Weickhardt AJ; Lu X; Maxon DA; Barón AE; Chonchol M; Camidge DR
Cancer; 2014 Mar; 120(5):664-74. PubMed ID: 24258622
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Efficacy of Crizotinib in Advanced ALK Positive
Non-small Cell Lung Cancer].
Zhao J; Zhang K; Zhang L; Wang H
Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):616-20. PubMed ID: 26483333
[TBL] [Abstract][Full Text] [Related]
5. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib-induced pancreatic pseudocyst: a novel adverse event.
Ishida H; Ichikawa W; Sasaki Y
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26351314
[TBL] [Abstract][Full Text] [Related]
7. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
[TBL] [Abstract][Full Text] [Related]
8. Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer.
Brosseau S; Gounant V; Choudat L; Pluvy J; Zalcman G; Khalil A
Diagn Interv Imaging; 2018 Apr; 99(4):267-268. PubMed ID: 29472032
[No Abstract] [Full Text] [Related]
9. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose.
Ripault MP; Pinzani V; Fayolle V; Pageaux GP; Larrey D
Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):e21-3. PubMed ID: 23182672
[No Abstract] [Full Text] [Related]
10. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma.
Kamide Y; Kaira K; Watanabe T; Kuribayashi S; Ozawa A; Koga Y; Ono A; Sunaga N; Hisada T; Oyama T; Yamada M
Intern Med; 2015; 54(22):2905-9. PubMed ID: 26568007
[TBL] [Abstract][Full Text] [Related]
12. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with ceritinib after crizotinib induced hepatitis.
Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
15. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
[TBL] [Abstract][Full Text] [Related]
16. A Drug Interaction between Crizotinib and Warfarin in Non-Small-Cell Lung Cancer: A Case Report.
Kubomura Y; Ise Y; Wako T; Katayama S; Noro R; Kubota K
J Nippon Med Sch; 2017; 84(6):291-293. PubMed ID: 29279560
[TBL] [Abstract][Full Text] [Related]
17. Widespread renal polycystosis induced by crizotinib.
Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P
Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.
Tartarone A; Gallucci G; Lazzari C; Lerose R; Lombardi L; Aieta M
Future Oncol; 2015; 11(14):2043-8. PubMed ID: 26198834
[TBL] [Abstract][Full Text] [Related]
19. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.
Awad MM; Lax TP; Slawski BR; Shaw AT
J Thorac Oncol; 2014 Nov; 9(11):1726-8. PubMed ID: 25436807
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]